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Abstract
Impairments in intestinal barrier function, epithelial mucins, and tight junction proteins have
been reported to be associated with nonalcoholic steatohepatitis. Prebiotic fructo-oligosac-
charides restore balance in the gastrointestinal microbiome. This study was conducted to
determine the effects of dietary fructo-oligosaccharides on intestinal barrier function and
steatohepatitis in methionine–choline-deficient mice. Three groups of 12-week-old male
C57BL/6J mice were studied for 3 weeks; specifically, mice were fed a methionine–choline-
deficient diet, a methionine–choline-deficient diet plus 5% fructo-oligosaccharides in water,
or a normal control diet. Fecal bacteria, short-chain fatty acids, and immunoglobulin A (IgA)
levels were investigated. Histological and immunohistochemical examinations were per-
formed using mice livers for CD14 and Toll-like receptor-4 (TLR4) expression and intestinal
tissue samples for IgA and zonula occludens-1 expression in epithelial tight junctions. The
methionine–choline-deficient mice administered 5% fructo-oligosaccharides maintained a
normal gastrointestinal microbiome, whereas methionine–choline-deficient mice without
prebiotic supplementation displayed increases in Clostridium cluster XI and subcluster XIVa
populations and a reduction in Lactobacillales spp. counts. Methionine–choline-deficient
mice given 5% fructo-oligosaccharides exhibited significantly decreased hepatic steatosis
(p = 0.003), decreased liver inflammation (p = 0.005), a decreased proportion of CD14-posi-
tive Kupffer cells (p = 0.01), decreased expression of TLR4 (p = 0.04), and increases in fecal
short-chain fatty acid and IgA concentrations (p < 0.04) compared with the findings in methi-
onine–choline-deficient mice that were not administered this prebiotic. This study illustrated
that in the methionine–choline-deficient mouse model, dietary fructo-oligosaccharides can
restore normal gastrointestinal microflora and normal intestinal epithelial barrier function,
and decrease steatohepatitis. The findings support the role of prebiotics, such as fructo-oli-
gosaccharides, in maintaining a normal gastrointestinal microbiome; they also support the
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need for further studies on preventing or treating nonalcoholic steatohepatitis using dietary
fructo-oligosaccharides.
Introduction
Nonalcoholic fatty liver disease (NAFLD) is an organ phenotype in metabolic syndrome that is
often complicated by obesity, dyslipidemia, and diabetes mellitus [1]. Nonalcoholic steatohe-
patitis (NASH) is part of the spectrum of NAFLD, combined with hepatic inflammation and
fibrosis, leading to cirrhosis [2]. It was reported that the 5-year cumulative incidence of liver
cancer in Japanese patients with NASH and cirrhosis was 20% [3]. Regardless of the examina-
tion of many researchers, it is not apparent which factor promotes the progression of NAFLD
to NASH, and, therefore, a radical curative method is unknown.
According to an analysis of the microbial flora and a study of metabolic products, intestinal
bacteria participate in organic homeostasis and pathological changes in the living body [4].
Abnormality of the microbial flora is called dysbiosis, which denotes a lack of diversity of
intestinal bacteria because of a disorder of quantitative and qualitative balance [5]. Addition-
ally, in NASH, dysbiosis has been determined via fecal examination, and it is caused by an
unbalanced diet or obesity, suggesting that improvements of the microbial flora are correlated
with improvements of hepatic steatosis [6].
Dysbiosis leads to biological and immunological intestinal barrier dysfunction through
shortages of nutrients in intestinal epithelial cells and mucosal immune deficiency [7–9].
Recently, intestinal barrier dysfunction was noticed in the pathogenesis of NAFLD [10]. A key
component of the onset of NASH is the influx of a large amount of pathogen-associated molec-
ular patterns (PAMPs) through disrupted intestinal mucosal epithelium [11, 12] and Kupffer
cell hypersensitivity to PAMPs in the liver [13].
After some animal experiments and clinical trials, it was revealed that amelioration of dys-
biosis improves intestinal barrier function, indicating that this strategy could represent an
effective treatment for certain diseases [14]. Prebiotics are food components that are not
digested or absorbed in the upper gastrointestinal tract. They are fermented selectively by ben-
eficial types of intestinal bacteria, favorably altering the composition of microbial flora and
conferring healthy effects on both the gastrointestinal tract and entire body of the host [15].
Prebiotics such as oligosaccharides and dietary fibers have such effects, and, in particular,
fructo-oligosaccharides (FOSs) meet all of the requirements to serve as probiotics. In this
study, to examine whether FOSs can be used to treat NASH, we hypothesized that FOSs can
improve dysbiosis and delay the onset of NASH, and examined the hypothesis using a NASH
animal model.
Materials and methods
Generation of the NASH mouse model
Six methionine–choline-deficient diet (MCD) mice (12-week-old male C57BL/6J mice, Sankyo
Labo Service Co. Inc., Tokyo, Japan) were fed an MCD (A02082002B, Research Diets Inc., New
Brunswick, NJ, USA) and purified water for 3 weeks and housed under conventional condi-
tions. In addition, six FOS-treated MCD (MCD + FOS) mice were additionally administered
5% FOS (Meioligo W, Meiji Co., Tokyo, JAPAN) in drinking water during the same period. Six
12-week-old male mice that were fed a control diet (A02082003B, Research Diets Inc.) and puri-
fied water for 3 weeks and maintained under the same conditions served as the control group.
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After the treatment period, 1.2 g of freshly collected feces were cryopreserved for analysis of
the microbial flora, short-chain fatty acid and IgA concentration.
After the mice were sacrificed by cervical dislocation, alanine aminotransferase (ALT) levels
were measured in serum samples prepared from venous blood. Mouse livers were extracted
after perfusion with phosphate-buffered saline (PBS) containing 0.5% bovine serum albumin
and 0.04% ethylenediaminetetraacetic acid (EDTA) (PBS buffer). Half of the liver was fixed in
4% paraformaldehyde (PFA) for hematoxylin–eosin (HE) staining and then evaluated patho-
logically according to the NAFLD activity score (NAS) [16]. The remainder of the liver was
used for flow cytometric analysis. The extracted the ileum, colon, and half of the cecum were
washed with PBS buffer and fixed in 4% PFA for HE and immunohistochemical staining. The
rest of the cecum was used for flow cytometric analysis. The IgA density of feces was measured
using a Mouse IgA ELISA Quantitation Kit (Bethyl Laboratories, Inc., Montgomery, TX,
USA). This study was performed in strict accordance with the recommendations in the Guide
for the Care and Use of Laboratory Animals of the National Institutes of Health. All efforts
were made to minimize suffering. The protocol was approved by the Teikyo University’s
School of Medicine’s Animal Ethics Committee (approval number: 14–030).
Analysis of the microbial flora and short-chain fatty acids in feces
To identify bacterial species, the partial amino acid sequence of 16S rDNA was analyzed using
the terminal restriction fragment length polymorphism method according to Nagashima’s
method [17]. Briefly, 20 mg of feces were dissolved in 0.2 ml of distilled water and washed by
centrifugation. The pellet was dissolved with 250 μl of TE buffer containing 100-mM Tris-HCl
and 40-mM EDTA. After centrifugation with 0.6 g of DNA-extraction beads, the supernatant
was collected and mixed with 150 μl of benzyl chloride and 50 μl of 10% sodium lauryl sulfate
for 30 min at 50˚C. After centrifugation with 150 μl of 3-M sodium acetate, the supernatant
was collected and mixed with isopropyl alcohol for DNA extraction. Next, 0.5 U of HotStarTaq
DNA polymerase (Qiagen, Tokyo, Japan) was added to 10 ng of DNA, and 16S rDNA was
amplified by polymerase chain reaction using the 50 terminal fluoro-labeled primers 516f and
1510r. After digestion with BslI, the fragment was analyzed using an ABI PRISM 3130xl DNA
Sequencer (Applied Biosystems, Carlsbad, CA, USA) and GeneMapper (Applied Biosystems).
The length of each fragment was distinguished using operational taxonomic units, and the
peak area ratio was presented as a percentage. One gram of feces was pulverized under sterile
conditions. Fecal short-chain fatty acids were analyzed using a Prominence high-performance
liquid chromatography system (Shimazu Corp., Kyoto, Japan).
Immunohistochemical staining
The 4% PFA-fixed tissue slices were subjected to an immuno-enzymatic method. Endogenous
peroxidase activity was blocked using H2O2 containing Tris-buffered saline (TBS). Then, over-
night incubation was performed with ×200 rabbit polyclonal anti-mouse zonula occludens-1
(ZO-1) (AVIVA Systems Biology Corp., San Diego, CA, USA), × 400 gout polyclonal anti-
mouse IgA (Gene Tex Inc., Irvine, CA, USA), and × 200 rabbit polyclonal anti-mouse TNF-
alpha (Lifespan Biosciences, Seattle, WA, USA). After washing with TBS-Tween, the tissue slices
were incubated with a peroxidase-conjugated immune polymer for primal antibodies (Envison-
PO for rabbit, Dako, Glostrup, Denmark) as a secondary antibody at room temperature for 1 h.
After washing with TBS, 3,30-diaminobenzidine was used for color development. Hematoxylin
was used for nuclear counterstaining. In the ileum and colon, IgA-positive cells were counted
in the range of 1 centimeter randomly selected. The mean number of IgA-positive cells was cal-
culated. Ileal villus heights were measured in the same range, and mean heights were calculated.
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Flow cytometric analysis
Hepatic and cecal mononuclear cells were isolated as follows: Mouse livers and the cecum
were filtered through a 40 μm cell strainer (BD Falcon, Durham, NC, USA) and re-suspended
in PBS buffer. The solution was centrifuged at 500 rpm for 5 min, and the supernatant was
centrifuged again at 1500 rpm for 5 min. After discarding the supernatant, the precipitate was
dissolved in PBS buffer, layered over 1.077-g/ml Lymphoprep (Axis-Shield Proc. AS, Oslo,
Norway), and centrifuged at 1500 rpm for 15 min. The mononuclear cell layer was collected
and washed with PBS buffer. Viable cell counting was performed using trypan blue staining.
Cells (1 × 106) were pre-incubated with 1 μl of purified anti-mouse CD16/32 (BioLegend,
San Diego, CA, USA) in 24 μl of cell-staining buffer (BioLegend) at 4˚C for 10 min and then
incubated with 25 μl of a solution containing cell-staining buffer and appropriate quantities of
fluorescein isothiocyanate-conjugated anti-mouse F4/80 and CD19 (BioLegend), phycoery-
thrin-conjugated anti-mouse CD14 (BioLegend), allophycocyanin (APC)/Alexa Fluor
750-conjugated anti-mouse CD11b (BioLegend), or APC-conjugated anti-mouse Toll-like
receptor 4 (TLR4) and CD38 (BioLegend) at 4˚C for 15 min in the dark. Rat IgG2a-kappa
(BioLegend) was used as the isotype control. Stained cells were washed, suspended in 200 μl of
PBS buffer, and dispensed into a 96-well round-bottom plate. Flow cytometric analyses were
performed using a BD FACSArray flow cytometer (BD Immunocytometry Systems, San Jose,
CA, USA) with FACSArray software (BD Immunocytometry Systems). Kupffer cells were
identified as the F4/80+ CD11b+. B cells were identified as the CD19+ cell population. The
mean fluorescence intensity (MFI) ratios of TLR4 and CD38 were calculated as the sample
MFI divided by the isotype control MFI.
Statistical analysis
Serum ALT levels, NAS, TLR4 MFI ratios, fecal short-chain fatty acid concentrations, numbers
of IgA-positive cells in the small intestine, fecal IgA concentrations, and cecal length are pre-
sented as the mean ± standard error mean. Statistical analysis was performed by the nonpara-
metric Mann–Whitney test and one-way ANOVA followed by Tukey post-test using
GraphPad Prism version 6.0 for Macintosh (GraphPad Software, San Diego, CA, USA), and
differences were considered significant at p< 0.05.
Results
MCD-induced dysbiosis and the effect of FOSs
To confirm whether dysbiosis occurs because of MCD, we analyzed mice feces. Regarding the
bacterial balance in feces of MCD mice compared with that in control mice’s feces, it was rec-
ognized that Clostridium cluster XI levels increased from 3% to 8.7%, and those of the Clostrid-
ium subcluster XIVa increased from 5.9% to 26.3%; on the contrary, counts of Lactobacillales
spp. decreased from 45.9% to 5.1% (Fig 1). FOSs improved the bacterial levels, considering
that after the treatment, the counts of Clostridium cluster XI and Clostridium subcluster XIVa
decreased to 4.6% and 2.7%, respectively, and those of Lactobacillales spp. increased to 27.1%,
in line with the bacterial balance of control mice. The color of feces in MCD mice was whitish,
compared to brownish in MCD + FOS and control mice, reflecting a change of the bacterial
balance.
Histological findings of the liver
To confirm whether MCD-induced NASH was improved by FOS, we analyzed serum ALT
and liver tissue samples. Serum ALT levels (72.2 ± 10.6 U/l) were significantly higher in MCD
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mice than in control mice (29.8 ± 1.8 U/l, p = 0.0004; Fig 2a), and macroscopically, the liver
was yellow (Fig 2b). Meanwhile, serum ALT levels (37.7 ± 7.3U/l) were significantly lower in
MCD + FOS mice than in MCD mice (p = 0.0005), and the liver was brownish, as observed in
control mice. Hepatic steatosis and inflammatory cell infiltrate were observed by HE staining
of liver tissue in MCD mice (Fig 2d), whereas those changes were restrained in MCD + FOS
mice. The NAS in MCD mice liver revealed scores of 2.3 ± 0.4, 1.8 ± 0.3, and 1.3 ± 0.4 points
for steatosis, centrilobular hepatitis, and ballooning degeneration, respectively, whereas the
value for each category was significantly decreased by 0.5 ± 0.5 points in MCD + FOS mice
(steatosis, p = 0.003; centrilobular hepatitis, p = 0.005; ballooning degeneration, p = 0.03; Fig
2c). TNF-alpha staining of the liver of MCD mice showed positive staining of hepatocyte sur-
rounding central vein; however, no staining was observed in FOS-treated mice (Fig 2e).
Histological findings of the small intestine
We hypothesized that MCD induces dysbiosis-mediated attenuation of intestinal barrier func-
tion, which would be improved by FOS; we analyzed villus heights and ZO-1 staining of the
ileum. Remarkable changes were not observed in MCD mice via HE staining of the ileal tis-
sues; however, villus extension was observed in MCD + FOS mice (Fig 3a). Villus heights were
significantly higher in MCD + FOS mice (221.9 ± 8.6 μm) than in Control (192.1 ± 10.9 μm)
and MCD mice (140.9 ± 25.2 μm) (p< 0.01). Length of the small intestine was longer in MCD
+ FOS mice (33.7 ± 5.6 mm) than in Control (30.1 ± 4.5 mm) and MCD mice (23.0 ± 2.7 mm)
(p< 0.01). Length of the small intestine was also longer in MCD + FOS mice (7.0 ± 3.9 mm)
than in MCD mice (5.1 ± 2.5 mm) (p = 0.02) but not significantly different from that in
Fig 1. Terminal restriction fragment length polymorphism analysis of microbiological flora and
macroscopic findings of feces from control, methionine–choline-deficient diet (MCD)-fed, and FOS-
treated MCD-fed mice.
https://doi.org/10.1371/journal.pone.0175406.g001
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Control mice (7.3 ± 2.1 mm). When we examined the expression of tight junction proteins via
ZO-1 staining, we recognized apical linear staining of the ileal epithelial cells and attenuation
of the staining in MCD mice (Fig 3b). FOSs improved ZO-1 staining.
Status of Kupffer cells
We hypothesized that MCD-mediated attenuation of intestinal barrier function could lead to
higher LPS-induced Kupffer cell activation as these cells are activated by TLR4. Thus we mea-
sured total and CD14+ Kupffer cell numbers and MFI ratio of TLR4 using flow cytometry.
The ratio of CD14+ cells among F4/80+ CD11b+ Kupffer cells was 8.1% ± 1.7% in control mice
versus 37.6% ± 6.7% in MCD mice (p = 0.01) and 14.5% ± 2.8% in MCD + FOS mice
(p = 0.01; Fig 4a). The number of total Kupffer cells was 984.7 ± 146.8 in control mice versus
3426.5 ± 663.3 in MCD mice (p = 0.003) and 2612.2 ± 452.5 in MCD + FOS mice (p = 0.07;
Fig 4b). CD14+ Kupffer cell counts were 81.2 ± 27.2 in control mice versus 1335.7 ± 454.7 in
MCD mice (p = 0.001) and 383.3 ± 101.4 in MCD + FOS mice (p = 0.002; Fig 4b). The MFI
ratio of TLR4 in CD14+ Kupffer cells was 7.8% ± 0.5% in control mice, compared to 10.6% ±
0.1% in MCD mice (p = 0.04) and 8.5% ± 0.2% in MCD + FOS mice (p = 0.04; Fig 4c).
Analysis of short-chain fatty acids in feces
We hypothesized that MCD-mediated attenuation of intestinal barrier function was due to a
reduction of Lactobacillales-produced short-chain fatty acids. Thus we measured short-chain
fatty acids in feces. Upon analyzing short-chain fatty acids in feces, it was recognized that the
concentrations of acetic acid (0.5 ± 0.1 mg/g, vs. Control’s 2.2 ± 0.1 mg/g; p = 0.003), propionic
Fig 2. MCD-fed mice with or without FOS treatment. A. Mean values of serum alanine aminotransferase
(ALT). *** p < 0.001. B. Macroscopic findings of the liver. C. Nonalcoholic fatty liver disease activity score.
** p < 0.01, * p = 0.03. Histological findings of the liver (D. hematoxylin–eosin stain, E. TNF-alpha stain.
× 100. Bar = 100 μm).
https://doi.org/10.1371/journal.pone.0175406.g002
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acid (0.1 ± 0.1 mg/g, vs. Control’s 0.4 ± 0.1 mg/g; p = 0.002), and n-butyric acid (0.1 ± 0.1 mg/
g, vs. Control’s 0.6 ± 0.1 mg/g, p = 0.003) were significantly decreased in MCD mice (Fig 5). In
MCD + FOS mice, the concentrations of acetic acid (0.9 ± 0.3 mg/g; p = 0.04) and propionic
acid (0.2 ± 0.1 mg/g; p = 0.001) were significantly improved, whereas that of n-butyric acid
(0.6 ± 0.1 mg/g; p = 0.002) was improved to control levels.
Analysis of IgA-producing process
We hypothesized that MCD-mediated attenuation of intestinal barrier function would include
not only disruption of tight junctions but also that of mucosal immunity due reduced IgA pro-
duction. Thus, we analyzed IgA-positive cells in ileal and colonic tissues. In the ileal tissue,
there were more IgA-positive cells in MCD + FOS mice (155.2 ± 8.7 cells) than in Control
(121.2 ± 10.9 cells) and MCD mice (98.4 ± 15.0 cells) (p = 0.001). It was similar in the colonic
tissue: there were more IgA-positive cells in MCD + FOS mice (89.1 ± 13.3 cells) than in
Fig 3. A. Mean villus heights (** p < 0.01) hematoxylin–eosin (HE, ×400. Bar = 50 μm) and B. zonula
occludens-1 (ZO-1, ×600. Bar = 50 μm) staining in the ileal villus epithelium of methionine–choline-deficient
diet-fed mice with or without the fructo-oligosaccharide treatment. C. Serumendotoxin level. * p < 0.05.
https://doi.org/10.1371/journal.pone.0175406.g003
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Control (79.3 ± 21.1) and MCD mice (66.4 ± 8.4 cells) (p = 0.03) (Fig 6b). It was recognized
that the IgA concentration in feces was 1.3 ± 0.1 μg/g in control mice, compared to
1.0 ± 0.1 μg/g in MCD mice (p = 0.01; Fig 6c) and 1.7 ± 0.1 μg/g in MCD + FOS mice
(p = 0.003).
MCD mice exhibited significant weight loss (18.8 ± 1.2 g, vs. Control’s 28.0 ± 1.3 g;
p = 0.003) and shortening of cecal length (14.3 ± 0.1 mm, vs. Control’s 26.8 ± 0.1 mm;
p = 0.004; Fig 7a and 7b). Although MCD + FOS mice had a similar weight as that of MCD
mice (19.7 ± 1.1 g; p = 0.3), cecal length was longer in MCD + FOS mice than in MCD mice
(31.8 ± 0.1 mm; p = 0.003). When we performed IgA staining of the cecal patch to investigate
the IgA-producing cells, we observed IgA-positive cells in the follicle and germinal center of
control and MCD + FOS mice, which we hardly observed in MCD mice (Fig 7c and 7d). To
identify whether FOS can differentiate cecal patch B cells to IgA-producing cells, we analyzed
B cells in cecal patch using flow cytometry. The number of CD19+ cells in the cecal patch
showed no difference in each group (Fig 7e), but CD38, a B cell activation marker, was
expressed more in MCD + FOS mice (2.5 ± 0.2) than in MCD mice (1.7 ± 0.3) (p = 0.02)
(Fig 7f).
Fig 4. Flow cytometric analysis of F4/80+ CD11b+ Kupffer cells in the livers of MCD-fed mice with or
without FOS treatment. A, Frequency of CD14+ Kupffer cells. B, Cell counts of total Kupffer cells and CD14+
Kupffer cells. * p < 0.05. C. Mean fluorescence intensity ratio of Toll-like receptor 4 in CD14− and CD14+
Kupffer cells. * p < 0.05.
https://doi.org/10.1371/journal.pone.0175406.g004
Fig 5. Fecal short-chain fatty acid concentrations of MCD-fed mice with or without FOS treatment. *
p = 0.04, ** p < 0.01.
https://doi.org/10.1371/journal.pone.0175406.g005
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Discussion
Mice that were fed an MCD developed steatohepatitis because large quantities of free fatty
acids from white adipose tissue flow into the liver [18] and hepatic VLDL secretion is impaired
[19]. As a limitation of this MCD-fed NASH animal model, the model does not reflect obesity
or insulin resistance, but there is merit to causing NASH in the short term in comparison with
high-fat diet feeding [20].
The existence of dysbiosis in NASH was reported as follows: decreased Bacteroides spp. and
increased Proteobacteria, Escherichia, or Clostridium coccoides [21, 22] from an examination of
patient feces and decreased Lactobacillales [23] in an MCD animal model.
In this study, we hypothesized that improvements of dysbiosis induced by FOSs can delay
the onset of NASH, and examined this hypothesis in mice fed an MCD. Compared to control
mice, Clostridium cluster counts were increased and those of Lactobacillales spp. were
decreased in the feces of MCD mice. Concentrations of short-chain fatty acids and IgA in feces
were also decreased. ZO-1 staining between ileal intraepithelial cells was diminished. In the
liver, fibrosis was not observed because of the short duration of examination, but hepatic stea-
tosis and inflammatory cell infiltration were observed. The percentage of CD14-positive Kupf-
fer cells was increased, and TLR4 expression in these cells was upregulated.
As shown in Fig 8, the mechanism of intestinal barrier dysfunction is believed to be associ-
ated with decreased short-chain fatty acid production by intestinal bacteria, resulting in the
depletion of energy sources for intestinal epithelial cells and a disordered homeostasis of intes-
tinal mucosal immunity [7–9]. Through the disrupted intestinal barrier, it is assumed that
Fig 6. Immunohistochemical evaluation of IgA in ileal and colonic tissues and fecal IgA
concentrations of MCD-fed mice with or without FOS treatment. A. Villus IgA staining in each group
(× 600. Bar = 100 μm). B. Villus IgA-positive cells in each group. ** p < 0.01. C. Fecal IgA concentration in
each group. * p = 0.01, ** p = 0.003.
https://doi.org/10.1371/journal.pone.0175406.g006
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PAMPs flow into the liver in large quantities [11, 12] and accelerate the production of inflam-
matory cytokines by Kupffer cells. Some reports identified high concentrations of endotoxin
in the portal venous blood [11, 12] and enhanced expression of CD14 and TLR4 in Kupffer
cells [13].
It is reported that FOSs increase Bifidobacterium and Lactobacillales spp. counts in the gas-
trointestinal tract. These bacteria produce short-chain fatty acids, which strengthen tight junc-
tions by nourishing intestinal epithelial cells [9, 14, 24], as well as stimulate the differentiation
Fig 7. Cecal findings of MCD-fed mice with or without FOS treatment. A. and B. Macroscopic findings
and mean length of the cecum in each group. ** p < 0.01. C. IgA staining of the cecal patch in each group
(× 600. Bar = 100 μm). GC denotes germinal center. D. IgA-positive cell counts in each group. ** p < 0.01. E.
Flow cytometric analysis of CD19+ B cell numbers (E) and mean fluorescence intensity ratio of CD38 (F) in
each group. * p = 0.02.
https://doi.org/10.1371/journal.pone.0175406.g007
Fig 8. The supposed mechanism by which dysbiosis influences nonalcoholic steatohepatitis and its
regulation by fructo-oligosaccharides.
https://doi.org/10.1371/journal.pone.0175406.g008
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of IgA-producing cells in the cecum and promote IgA secretion from intestinal mucosa [25,
26]. Our examination using MCD mice revealed that FOSs improved dysbiosis, increased Lac-
tobacillales spp. counts, enhanced short-chain fatty acid production by intestinal bacteria, and
improved ZO-1 staining in tight junctions. FOSs increased the number of IgA-positive cells in
the germinal center of cecal patches and significantly reinforced IgA secretion by intestinal
villi. Surprisingly, hepatic steatosis and inflammatory cell infiltration were decreased by FOS
administration. The percentage of CD14-positive Kupffer cells and expression of TLR4 were
also decreased. This report is the first to demonstrate that FOSs controlled the onset of NASH.
This study was a small animal study with a short duration; in fact, no liver fibrosis was
observed. This study is preliminary, and it should be followed by larger studies with longer
durations to clarify the implications for human NASH. Together with the fact that we did not
use another NASH model animal, these are limitations of our study; our findings support FOS
administration as an effective treatment for NASH.
As a reason why steatohepatitis was improved by FOS administration, changes of the
microbial flora may accelerate β-oxidation in the liver [27, 28]. In addition, short-chain fatty
acids may both enhance intestinal barrier function and improve NASH directly. Adipose tissue
expresses short-chain fatty acid receptors, which act to improve insulin resistance in the liver
and muscle by inhibiting fat accumulation [29]. Furthermore, short-chain fatty acids act on
the L cells of the intestinal tract, which promote GLP-1 secretion [30]. Further examination
will reveal the direct action of FOSs in the liver.
Some methods to resolve dysbiosis have been reported. Recently, it was demonstrated that
fecal microbiota transplantation (FMT) from healthy people is effective for treating patients with
recurrent Clostridium infection [31]. The effectiveness of FMT in treating inflammatory bowel
disease and irritable bowel syndrome, which are thought to involve dysbiosis, has also been sug-
gested [32]. Serious side effects of FMT were not reported, but an evaluation of its effectiveness
and safety is underway in Japan. Meanwhile, the replacement of useful bacteria as probiotics has
been examined in NASH animal models. Velayudham et al. confirmed the downregulation of
TLR4 and CD14 mRNA expression in the liver and the attenuation of hepatic fibrosis in MCD
mice fed VSL#3, which is a probiotic that includes eight types of useful bacteria, for 10 weeks.
However, they could not confirm a significant suppressive effect on hepatic steatosis and inflam-
mation [33]. Endo et al. confirmed the reinforcement of tight junctions between intestinal epi-
thelial cells and improvements of hepatic steatosis and fibrosis of choline-deficient/L-amino
acid-defined diet-fed rats administered butyric acid-producing bacteria for 8–50 weeks [34].
However, it is difficult to reverse dysbiosis through the administration of single bacteria species.
To date, there is no approved therapy for improving NASH. Our study provided a potential
dietary strategy for preventing and treating NASH. Prebiotics such as FOSs are present in
onions, garlic, soybeans, and burdock, or are produced industrially as a syrup. They are more
capable of being easily consumed habitually and continuously than probiotics. We believe
FOSs can greatly contribute to a healthy life.
In conclusion, this study illustrated that in the MCD mouse model, dietary FOSs can restore
the normal gastrointestinal microflora and normal intestinal epithelial barrier function and
decrease steatohepatitis. The findings support the role of prebiotics such as FOSs in maintain-
ing a normal gastrointestinal microbiome; they also support the need for further studies on the
prevention or treatment of NASH using dietary FOSs.
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